Alignment Healthcare (NASDAQ: ALHC) reported in an SEC filing that Chief Executive Officer John E. Kao sold a total of 48,900 shares of the company’s common stock on March 12, 2026. The dispositions were carried out in two separate transactions and together generated proceeds of $853,125.
Details filed with regulators show the larger of the two trades involved 45,938 shares sold at a weighted-average price of $17.476 per share, producing $802,838 in proceeds. The trade executed within a price range of $17.035 to $18.03. The second transaction covered 2,961 shares sold at a weighted-average price of $16.9919 per share, for $50,287 total; that batch traded between $16.92 and $17.03.
The filing indicates the share sales were to satisfy tax withholding obligations generated by the vesting of restricted stock units and were not discretionary transactions by Mr. Kao. After the reported sales, Kao is listed as directly owning 1,519,480 shares of Alignment Healthcare. He also retains an indirect stake of 2,472,641 shares through the JEK Trust dated February 8, 2021, in which he serves as trustee.
Market context noted in the filing and related commentary shows Alignment Healthcare’s stock has fallen 7.9% over the prior week, while the company holds a market capitalization of $3.47 billion. Analysts covering the company continue to publish price targets within a broad range, from $18 to $30 per share. An InvestingPro analysis cited in the filing indicates the stock is currently trading below its estimated Fair Value. Investors seeking deeper company-specific equity research are directed to the Pro Research Report that covers ALHC among more than 1,400 U.S. equities.
Corporate results released recently underpin some of the optimism among analysts. Alignment Healthcare’s fourth-quarter performance included a 25% year-over-year increase in membership and a 44.4% rise in revenue, both results reported as exceeding expectations. In response to those results, Raymond James reiterated a Strong Buy rating and set a $27.00 price target. Piper Sandler maintained an Overweight rating and a $30.00 price target after noting that the company’s reported medical benefit ratio and adjusted EBITDA beat projections.
Separately, the company disclosed an affiliated secondary offering in which 13.2 million shares were priced at $19.46 apiece. That offering is being conducted by an affiliate of General Atlantic, L.P.; Alignment Healthcare will not receive proceeds from the sale. The offering was expected to close in March 2026, with J.P. Morgan acting as underwriter. Company statements and analyst commentary included with the filing characterize these developments as evidence of ongoing investor interest and analyst confidence in the company’s financial performance and prospects.
Context and implications
The SEC filing frames the CEO’s sales as mechanistic tax-withholding transactions connected to RSU vesting rather than discretionary stock sales. At the same time, recent operational results and continuing analyst support are noted in the public record, as is the affiliate-led secondary offering that is in the market through March 2026.